IDA total vs Switzerland: Access to anti-retroviral drugs, male
IDA total
78.2%
in 2024
Switzerland
90.0%
in 2023
IDA total rank
11th
Switzerland rank
13th
Access to anti-retroviral drugs, male over time
- IDA total
- Switzerland
How they compare
Switzerland currently reports 90.0% against 78.2% in IDA total, a difference of 11.8%.
That makes Switzerland's figure about 1.2 times IDA total's.
Across all 24 years both countries report, Switzerland has been ahead every year.
IDA total ranks 11th and Switzerland ranks 13th of 19 groups.
Switzerland has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | IDA total | Switzerland | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 5.6% | 50.0% | 44.4% | Switzerland |
| 2010s | 39.4% | 79.2% | 39.8% | Switzerland |
| 2020s | 69.3% | 90.2% | 20.9% | Switzerland |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, IDA total or Switzerland?
- Switzerland, at 90.0% against 78.2% in IDA total as of 2023.
- What is the difference in access to anti-retroviral drugs, male between IDA total and Switzerland?
- 11.8%, with Switzerland ahead.
- How many years of comparable data are there for IDA total and Switzerland?
- 24 years are reported by both, from 2000 to 2023.
- How do IDA total and Switzerland rank globally for access to anti-retroviral drugs, male?
- IDA total ranks 11th and Switzerland ranks 13th of 19 groups.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.